Compare ACCO & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | FULC |
|---|---|---|
| Founded | 1893 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 285.4M |
| IPO Year | 2005 | 2019 |
| Metric | ACCO | FULC |
|---|---|---|
| Price | $4.38 | $3.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.00 | $3.67 |
| AVG Volume (30 Days) | 535.4K | ★ 1.2M |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | ★ 6.91% | N/A |
| EPS Growth | ★ 141.51 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,524,700,000.00 | N/A |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $1.71 | N/A |
| P/E Ratio | $12.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.81 | $2.83 |
| 52 Week High | $4.56 | $15.74 |
| Indicator | ACCO | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 38.13 |
| Support Level | $4.15 | $3.62 |
| Resistance Level | $4.56 | $3.91 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 100.00 | 10.26 |
ACCO Brands Corp is a consumer, technology and business branded products company providing brands and product solutions used in schools, homes and at work. Its brands include At-A-Glance, Barrilito, Buro, Esselte, Five Star, Foroni, GBC, Hilroy, Kensington, Leitz, Mead, PowerA, Quartet, Rapid, Swingline and Tilibra. The Company's product categories include gaming and computer accessories, storage and organization, notebooks, shredding, laminating and binding machines, dry erase boards and do-it-yourself tools. The Company operates through two segments, Americas and International. Americas includes the U.S., Canada, Brazil, Mexico and Chile, and International includes EMEA, Australia, New Zealand and Asia. Its products are sold in the U.S., Europe, Australia, Canada, Brazil and Mexico.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.